Sign up Australia
Proactive Investors - Run By Investors For Investors

Medlab Clinical to begin trials of cannabis based medicines

Expected to meet a global need for better cancer pain management.
Medlab Clinical to begin trials of cannabis based medicines
Both clinical trials have received ethics committee approvals

Medlab Clinical (ASX:MDC) has received approvals to begin human trials of two different cannabis based medicines – NanaBis and NanaBidial.

NanaBis is packaged as a mouth spray and will be clinically tested in advanced stage cancer patients with intractable pain.

The drug is expected to meet a global need for better pain management, with research having shown cancer pain was an increasingly widespread condition.

Recent statistics regarding cancer pain indicate it is prevalent in 64% of patients with metastatic or advanced-stage disease and that for one in two patients with cancer, it is undertreated.

With the recent U.S. crackdown on opioid abuse, there is a significant need for better, efficacious treatment.

NanaBidial comprises cannabidiol derived from marijuana and is indicated for chemotherapy induced nausea and vomiting, with a secondary endpoint in patients suffering seizures.

The drug is intended to be made available to general practitioners so it would give many Australians access to a drug which governments around the country have been keen to see introduced.

Both clinical trials have received Human Research Ethics Committee (HREC) approvals and are expected to commence shortly.

Recent research on the legal cannabis industry in North America showed consumers spent US$6.9 billion on legal cannabis products in 2016, up 34% from 2015.





Register here to be notified of future MDC Company articles
View full MDC profile View Profile

Medlab Clinical Timeline

Related Articles

Frosties Box
December 05 2017
The company is a pioneer in the human microbiome, which is essentially the bacteria that inhabits the gut and skin
1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
the word antioxidant
August 15 2017
The heparin test is the firm’s lead product; however the company’s OxiChek device for oxidative stress is also gaining traction

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use